PTC Therapeutics, Inc. (NASDAQ: PTCT) posts Q2 2026 profit, Phase 3 HD trial
PTC Therapeutics, Inc. (NASDAQ: PTCT) posts Q2 2026 profit, Phase 3 HD trial PTC Therapeutics, Inc. reported strong Q2 2026 results, with total revenues of $360.5 million, up from $178.9 million a year earlier. Growth was driven by net product revenue of $238.8 million and collaboration and license revenue of $50.6 million, including a $50.0 million milestone from Novartis for Huntington’s disease candidate votoplam. Royalty revenue contributed $71.1 million.
How this was made
The 30-second read
Why it matters
Traders can update PTCT’s near-term fundamentals using the reported revenue/EPS and cash runway, while also repricing clinical and partnership risk based on the Phase 3 votoplam trial commencement and planned upcoming studies.
Market read
A profitable quarter with a sizable Novartis milestone and multiple trial milestones can drive a reassessment of PTCT’s cash-flow durability and probability-weighted pipeline value.
What to watch
The article highlights a large liability for sale of future Evrysdi royalties and a stockholder deficit, so leverage and royalty economics could cap upside despite the cash balance.
Background
PTC Therapeutics reported Q2 2026 results and provided an update across commercial products (including Sephience for PKU) and multiple pipeline programs (votoplam, PTC612, PTC844, vatiquinone).
Ticker impact
PTC reported Q2 2026 revenues of $360.5M, net income $83.5M, and outlined multiple clinical-stage updates including a Phase 3 votoplam trial.
Likely positive bias for PTCT on earnings-day trading, with follow-through tied to how investors underwrite the votoplam Phase 3 and ongoing liquidity runway.
The article provides concrete financial datapoints (revenue, EPS, cash, debt) plus specific program milestones and funding runway for at least 12 months, which are actionable for valuation and risk models.
Market effects
Biopharma investors may read the Novartis milestone and Phase 3 start as improved partner confidence in Huntington’s disease assets.
Limited direct regional impact; approvals and trial activity are global but not tied to a single market shock.
Global collaboration milestone and multinational Phase 3 initiation can influence sentiment across rare-disease and neurodegeneration peers.
Counterpoint
Profitability and revenue growth may be partly milestone-driven and not yet reflective of durable, recurring product demand; dilution risk remains via the unused ATM facility.
Key entities
- companyPTC Therapeutics, Inc.
Reported Q2 2026 financial results, cash/debt position, and clinical program timelines including a Phase 3 votoplam trial.
- partnerNovartis
Provided a $50.0M milestone for PTC’s Huntington’s disease candidate votoplam and commenced a global Phase 3 trial.